Artelo Biosciences (ARTL) announced the pricing of its previously announced underwritten public offering of 441,210 shares of its common stock at a price to the public of $4.40 per share and pre-funded warrants to purchase up to 13,335 shares of Artelo’s common stock at a price to the public of $4.399 per pre-funded warrant, which represents the per share public offering price of each share of Artelo’s common stock less the $0.001 per share exercise price for each pre-funded warrant. The aggregate gross proceeds from the offering are expected to be approximately $2.0 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 68,181 shares of common stock at the public offering price per share, less the underwriting discounts to cover over-allotments, if any. The offering is expected to close on October 1, 2025, subject to satisfaction of customary closing conditions. R.F. Lafferty & Co., Inc. is acting as the sole book-running manager for the offering.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARTL:
- Artelo Biosciences files to sell common stock, no amount given
- Artelo Biosciences presents interim Phase 2 CAReS data on ART27.13
- Artelo Biosciences Completes Stock Offering with Over-Allotment
- Artelo Biosciences announces publication of preclinical data on ART12.11
- Artelo Biosciences Updates Bylaws on September 9, 2025
